When you are considering medication for ADHD, a useful place to begin is everyday life. What would you like to become easier: staying with a conversation, finishing a task, managing a deadline, or pausing before acting?

Stimulants and non-stimulants can both have a place in adult ADHD care. They differ in how quickly benefits appear, their side effects, and how they fit a person’s medical history. Choosing a treatment means putting the evidence alongside your priorities.

Two categories, several options.

Stimulants include methylphenidate-based and amphetamine-based medications, including lisdexamfetamine. They come in different formulations, with different durations of effect. [1]

Non-stimulants include atomoxetine and extended-release viloxazine (Qelbree), both FDA-approved for adult ADHD in the United States. Other medications, such as bupropion, are sometimes prescribed off-label. Off-label means the FDA has not approved the medication for that particular use; the reason for choosing it should be part of the conversation. [2] [3] [4]

“Non-stimulant” describes a category, not a single mechanism, level of effectiveness, or safety profile. The specific medication matters.

What differs in practice?

Stimulants and commonly used adult non-stimulants at a glance
ConsiderationStimulantsAtomoxetine / viloxazine ER
When benefits appearEffects often begin on the day a dose is taken.Benefits generally build over weeks of consistent treatment.
How treatment is adjustedDose, timing, and formulation can affect coverage and tolerability.Dose and time on treatment matter when judging benefit.
Possible side effectsAppetite loss, sleep difficulty, headache, stomach upset, or irritability.Nausea, appetite changes, dry mouth, constipation, fatigue, or sleep changes; effects differ by medication.
Follow-upSymptoms, daily functioning, blood pressure, pulse, sleep, appetite, and mood.The same areas need attention, along with medication-specific warnings and interactions.

This is a general comparison, not a complete list of effects or risks. Both categories can raise blood pressure and heart rate. [1] [2] [3] [5]

A quick onset does not mean the first prescription will be the right fit. With either approach, finding a helpful dose and a manageable side-effect profile can take time. Ask when you should expect an early change and when you will review the overall result.

What does the research tell us?

Adult trials support symptom improvement with stimulants and atomoxetine. Some comparisons favor stimulants, particularly amphetamine medications, for average short-term symptom reduction. The size of the difference depends on the medication, the outcome measured, and who rates the symptoms. [4] [6]

A 2025 review found benefits for both stimulants and atomoxetine on clinician-rated and self-rated ADHD symptoms around 12 weeks. Evidence about longer-term outcomes was more limited. A group average cannot predict which treatment will help one person most, and symptom scores do not tell the whole story of daily life. [6]

For example: “I want to finish routine work without repeatedly losing track,” or “I want to listen without interrupting.” These examples can give follow-up appointments a clearer focus.

What makes an option a good fit?

Your clinician considers your health history, other medications, past treatment response, and preferences. Sleep, appetite, cardiovascular health, mood symptoms, and substance use are relevant to that assessment. Cost, insurance coverage, and availability also affect whether a plan is practical. [7]

A non-stimulant may be a reasonable option when a stimulant is unsuitable, has not helped enough, causes difficult side effects, or is not preferred. A stimulant may be a reasonable option when its expected benefits and risks fit your circumstances. The decision can be revisited as you learn what helps.

Both approaches need follow-up.

Bring changes in sleep, appetite, weight, mood, or physical symptoms to your prescriber. Atomoxetine can also cause sexual or urinary side effects. Read the medication guide for the specific product and review other prescriptions, over-the-counter medicines, and supplements with your clinician or pharmacist. [2] [7]

  • Stimulants carry boxed warnings about misuse, abuse, addiction, and overdose. Take them as prescribed, store them securely, and never share them. [1]
  • Atomoxetine has a boxed warning about suicidal thoughts in children and adolescents; the label’s analysis of adult trials did not show the same increase. It also has important warnings, including rare severe liver injury. [2]
  • Viloxazine ER has a boxed warning about suicidal thoughts and behaviors in both pediatric and adult patients, as well as important interaction and mood-activation warnings. [3]

Seek urgent medical help for severe symptoms such as chest pain, fainting, or new suicidal thoughts. Contact your prescriber promptly about concerning changes; do not wait for a routine follow-up.

Medication is one part of the plan.

ADHD-focused therapy can help with organization, planning, and coping. Practical supports—such as reminders, smaller task steps, consistent places for essentials, and changes to the work environment—can be useful alongside treatment. Sleep and other mental or physical health concerns deserve attention too. [8]

Bring to your next appointment

Four questions worth asking

  1. What are we hoping this medication will help me do more easily?
  2. When should we assess whether it is helping?
  3. Which side effects or changes should prompt a call?
  4. What will we consider if the benefit is incomplete or the side effects are difficult?

The aim is a treatment plan you understand, can take part in, and can review honestly over time.

Sources & further reading

Sources checked October 18, 2026. Medication information and guidance can change.

  1. FDA: Prescription stimulant safety information
  2. DailyMed: Atomoxetine prescribing information
  3. DailyMed: Qelbree (viloxazine ER) prescribing information
  4. Cortese et al. (2018): Comparative efficacy and tolerability of ADHD medications
  5. NIMH: Dr. Mary Rooney discusses managing ADHD (2020; onset discussion)
  6. Ostinelli et al. (2025): Comparative efficacy and acceptability of adult ADHD interventions
  7. NIMH: Mental health medications
  8. NIMH: ADHD in adults—4 things to know

General education, not a personal diagnosis or treatment plan. Discuss medication changes with your prescriber.

Care at Thoughtscape

Bring your questions.

Learn about adult ADHD assessment and care with Jeffrey Panko, PMHNP-BC.

Explore adult ADHD care